Epigenomics AG / Key word(s): Issue of Debt/Corporate ActionEpigenomics AG: Reduction of principal amount of planned mandatory convertible bond to up to EUR 16.5 million and of conversion price to EUR 1.10 per share 20-Aug-2021 / 10:41 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by […]
Category: Insider Information
20. August 2021
Epigenomics AG: Reduction of principal amount of planned mandatory convertible bond to up to EUR 16.5 million and of conversion price to EUR 1.10 per share
Read more
17. August 2021
Epigenomics AG: Execution of a Biobank Sale Agreement and Update of Guidance
Epigenomics AG / Key word(s): Strategic Company Decision/Change in ForecastEpigenomics AG: Execution of a Biobank Sale Agreement and Update of Guidance 17-Aug-2021 / 21:00 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP – a service of EQS Group AG.The issuer is solely responsible for […]
11. June 2021
Epigenomics AG plans to issue mandatory convertible bond in the amount of up to EUR 18.15 million
Epigenomics AG / Key word(s): Bond/FinancingEpigenomics AG plans to issue mandatory convertible bond in the amount of up to EUR 18.15 million 11-Jun-2021 / 21:05 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP – a service of EQS Group AG.The issuer is solely responsible […]
18. May 2021
Epigenomics AG successfully completes capital increase
Epigenomics AG / Key word(s): Capital IncreaseEpigenomics AG successfully completes capital increase 18-May-2021 / 08:51 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP – a service of EQS Group AG.The issuer is solely responsible for the content of this announcement. NOT FOR PUBLICATION, DISTRIBUTION […]
27. April 2021
Epigenomics AG decides to increase share capital through rights issue with subscription rights of existing shareholders
Epigenomics AG / Key word(s): Capital IncreaseEpigenomics AG decides to increase share capital through rights issue with subscription rights of existing shareholders 27-Apr-2021 / 17:31 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP – a service of EQS Group AG.The issuer is solely responsible […]
25. March 2021
Epigenomics AG is Evaluating M&A Options
Epigenomics AG / Key word(s): Strategic Company DecisionEpigenomics AG is Evaluating M&A Options 25-March-2021 / 10:48 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP – a service of EQS Group AG.The issuer is solely responsible for the content of this announcement. NOT TO BE […]